Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa reported option exercises and share sales in common stock. On June 1, 2026, Randhawa exercised stock options for a total of 26,530 shares of common stock at exercise prices between $8.44 and $22.07 per share.
On the same date, Randhawa sold 26,530 shares of common stock in open-market transactions at weighted average prices reported as $89.72, $90.72, and $91.37 per share, with actual trade prices ranging from $89.17 to $91.96. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, indicating the transactions were scheduled in advance.
DNTH filing of a Form 144 notifies the proposed sale of 26,530 shares of Common Stock via an exercise of stock options on 06/01/2026. The filing lists 2467555.30 (amount) and a figure 54,666,233 in the securities section. It also discloses prior 10b5-1 sales: 33,830 shares on 03/12/2026 with 2756333.08 (amount).
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date.
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.
The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.
According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.
Dianthus Therapeutics director Anne McGeorge received a grant of stock options, not a market purchase or sale. The award covers 6,090 options to buy common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving the company through that vesting date.
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.
Dianthus Therapeutics director Jonathan Violin received a compensation-related stock option grant. He was awarded options to purchase 6,090 shares of common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that date. After this grant, he holds 6,090 stock options directly, with no open-market share purchases or sales reported in this filing.
Dianthus Therapeutics director Paula Soteropoulos received a grant of stock options covering 6,090 shares of common stock. These options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 derivative securities linked to common stock.
The underlying 6,090 shares of common stock will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through the vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Dianthus Therapeutics reported results from its annual stockholder meeting held on May 21, 2026. Stockholders elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting. An advisory vote approved executive compensation, with 41,004,507 votes for and 1,713,043 against. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,298,319 votes for and minimal opposition.